Skip to content

Evaluation of safety and efficacy of blue laser vaporization of prostatecte compared to TURP treatment in patients with = 80mL benign prostatic hyperplasia

Evaluation of safety and efficacy of blue laser vaporization of prostatecte compared to TURP treatment in patients with = 80mL benign prostatic hyperplasia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079490
Enrollment
Unknown
Registered
2024-01-04
Start date
2024-01-15
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostate Hyperplasia

Interventions

Test group:Transurethral blue laser vaporization of the prostate

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male aged 50-80; 2. IPSS>12, Qmax = 15mL/s (VV>150mL); 3. Prostate volume 30-80mL (transrectal ultrasound); 4. Patients with lower urinary tract symptoms and diagnosed with BPH who plan to undergo TURP surgery; 5. Voluntarily participate in clinical trials and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with concurrent bladder stones; 2. Difficulty in inserting instruments for urethral stricture (urethral conditions may hinder the insertion of bladder endoscope F20 and above); 3. Neurogenic lower urinary tract symptoms; 4. Prostate specific antigen exceeds the normal range and prostate cancer cannot be ruled out; 5. Patients with bladder cancer and other urothelial cancer; 6. Patients who have previously undergone BPH or urethral surgery; 7. Severe cardiovascular disease, lung disease, or other systemic diseases that cannot tolerate surgery; 8. Individuals who participate in other clinical trials related to prostate hyperplasia within the first three months of enrollment; 9. Patients who are unwilling to accept clinical research protocols.

Design outcomes

Primary

MeasureTime frame
International prostate symptom score, IPSS;Qmax;

Secondary

MeasureTime frame
QoL;PVR;VV;Operation time;IIEF-5;MSHQ-EjD;ICIQ-MLUTS-Urinary Symptoms;ICIQ-MLUTS-Sexual Function;Hemoglobin;Serum sodium;Complication;QoR VAS;Postoperative bladder irrigation time;Postoperative indwelling catheterization time;Postoperative hospitalization time;Postoperative bladder irrigation fluid volume;

Countries

China

Contacts

Public ContactLin Yang

The First Affiliated Hospital of Xi'an Jiaotong University

docyanglin@126.com+86 189 9123 2334

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026